Recurrence and poor prognosis following resection of small hepatitis B-related hepatocellular carcinoma lesions are associated with aberrant tumor expression profiles of glypican 3 and osteopontin

Annals of Surgical Oncology

Volumn 19, Issue SUPPL. 3, 2012, Pages

  Yu, Ming Chin ^a,b   Lee, Yun Shien ^a,c   Lin, Sey En ^d   Wu, Hsiang Yao ^b   Chen, Tse Ching ^b   Lee, Wei Chen ^a   Chen, Miin Fu ^a   Tsai, Chi Neu ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c MING CHUAN UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYPICAN 3; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HEPATITIS B; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL PROLIFERATION; CHEMOTAXIS; DISEASE-FREE SURVIVAL; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENES, NEOPLASM; GLYPICANS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPONTIN; PROPORTIONAL HAZARDS MODELS; UP-REGULATION;

EID: 84864978576     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1946-2     Document Type: Article

References (48)

1. FX Bosch J Ribes M Diaz R Cléries 2004 Primary liver cancer: worldwide incidence and trends Gastroenterology 127 S5 S16 15508102 10.1053/j.gastro.2004.09.011
2. Department of Health, Taiwan. Health statistics in Taiwan, 2006. http://www.doh.gov.tw/ufile/doc/Chapter%202.pdf.
3. DS Chen 2007 Hepatocellular carcinoma in Taiwan Hepatol Res 37 S101 S105 17877468 10.1111/j.1872-034X.2007.00170.x
4. CJ Chen HI Yang J Su CL Jen SL You SN Lu, et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA. 295 65 73 16391218 10.1001/jama.295.1.65 1:CAS:528: DC%2BD28XhtlKqtQ%3D%3D
5. SN Lu WW Su SS Yang TT Chang KS Cheng JC Wu, et al. 2006 Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan Int J Cancer. 119 1946 1952 16708389 10.1002/ijc.22045 1:CAS:528:DC%2BD28Xps1Snsbk%3D
6. LX Qin ZY Tang 2002 The prognostic significance of clinical and pathological features in hepatocellular carcinoma World J Gastroenterol. 8 193 199 11925590
7. WC Lee LB Jeng MF Chen 2002 Estimation of prognosis after hepatectomy for hepatocellular carcinoma Br J Surg. 89 311 316 11872055 10.1046/j.0007-1323. 2001.02034.x
8. PR Tung-Ping ST Fan J Wong 2000 Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma Ann Surg. 232 10 24 10.1097/00000658-200007000-00003
9. J Bruix JM Llovet 2002 Prognostic prediction and treatment strategy in hepatocellular carcinoma Hepatology. 35 519 524 11870363 10.1053/jhep.2002.32089
10. K Yanaga 2004 Current status of hepatic resection for hepatocellular carcinoma J Gastroenterol. 39 919 926 15549443 10.1007/s00535-004-1422-x
11. RT Poon ST Fan CM Lo CL Liu J Wong 2002 Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation Ann Surg. 235 373 382 11882759 10.1097/00000658-200203000-00009
12. Y Zhou Y Zhao B Li D Xu Z Yin F Xie, et al. 2010 Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma BMC Gastroenterol. 10 78 20618937 10.1186/1471-230X-10-78
13. BI Carr F Kanke M Wise S Satomura 2007 Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States Dig Dis Sci. 52 776 782 17253135 10.1007/s10620-006-9541-2 1:CAS:528:DC%2BD2sXhslWju74%3D
14. G Malaguarnera M Giordano I Paladina M Berretta A Cappellani M Malaguarnera 2010 Serum markers of hepatocellular carcinoma Dig Dis Sci. 55 2744 2755 20339916 10.1007/s10620-010-1184-7 1:CAS:528:DC%2BC3cXhtF2lurvP
15. X Ge S Yamamoto S Tsutsumi Y Midorikawa S Ihara SM Wang, et al. 2005 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues Genomics. 86 127 141 15950434 10.1016/j.ygeno.2005. 04.008 1:CAS:528:DC%2BD2MXlvV2nt7w%3D
16. MB Eisen PT Spellman PO Brown D Botstein 1998 Cluster analysis and display of genome-wide expression patterns Proc Natl Acad Sci USA. 95 14863 14868 9843981 10.1073/pnas.95.25.14863 1:CAS:528:DyaK1cXotVGmurk%3D
17. YS Lee CH Chen CN Tsai CL Tsai A Chao TH Wang 2009 Microarray labeling extension values: laboratory signatures for Affymetrix GeneChips Nucleic Acids Res. 37 1 12 10.1093/nar/gkn923
18. MC Ho JJ Lin CN Chen CC Chen H Lee CY Yang, et al. 2006 A gene expression profile for vascular invasion can predict the recurrence after resection of hepatocellular carcinoma: a microarray approach Ann Surg Oncol. 13 1474 1484 17009164 10.1245/s10434-006-9057-1
19. SM Wang LL Ooi KM Hui 2007 Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma Clin Cancer Res. 13 6275 6283 17975138 10.1158/1078-0432.CCR-06-2236 1:CAS:528:DC%2BD2sXht1Cgtb7L
20. N Iizuka M Oka H Yamada-Okabe M Nishida Y Maeda N Mori, et al. 2003 Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection Lancet. 361 923 929 12648972 10.1016/S0140-6736(03)12775-4 1:CAS:528:DC%2BD3sXitVKmtLg%3D
21. S Yoshioka I Takemasa H Nagano N Kittaka T Noda H Wada, et al. 2009 Molecular prediction of early recurrence after resection of hepatocellular carcinoma Eur J Cancer. 45 881 889 19167881 10.1016/j.ejca.2008.12.019 1:CAS:528:DC%2BD1MXisl2rsb0%3D
22. T Moribe N Iizuka T Miura N Kimura S Tamatsukuri H Ishitsuka, et al. 2009 Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma Int J Cancer. 125 388 397 19384946 10.1002/ijc.24394 1:CAS:528:DC%2BD1MXms1amu7k%3D
23. M Okamoto T Utsunomiya S Wakiyama M Hashimoto K Fukuzawa T Ezaki, et al. 2006 Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients Ann Surg Oncol. 13 947 954 16788756 10.1245/ASO.2006.07. 018
24. CF Lee ZQ Ling T Zhao KR Lee 2008 Distinct expression patterns in hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma World J Gastroenterol. 14 6072 6077 18932288 10.3748/wjg.14.6072
25. H Okabe S Satoh T Kato O Kitahara R Yanagawa Y Yamaoka, et al. 2001 Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression Cancer Res. 61 2129 2137 11280777 1:CAS:528: DC%2BD3MXit1Ogsbw%3D
26. SW Nam JY Park A Ramasamy S Shevade A Islam PM Long, et al. 2005 Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling Hepatology. 42 809 818 16175600 10.1002/hep.20878 1:CAS:528:DC%2BD2MXhtFGlsbjE
27. V Paradis I Bieche D Dargere I Laurendeau C Laurent P Bioulac Sage, et al. 2003 Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index Am J Pathol. 163 733 741 12875992 10.1016/S0002-9440(10)63700-5 1:CAS:528:DC%2BD3sXmslSntr8%3D
28. S Lee S Kim 2007 Gene regulations in HBV-related liver cirrhosis closely correlate with disease severity J Biochem Mol Biol. 40 814 824 17927917 10.5483/BMBRep.2007.40.5.814 1:CAS:528:DC%2BD2sXhtFKqs7rE
29. E Wurmbach YB Chen G Khitrov W Zhang S Roayaie M Schwartz, et al. 2007 Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma Hepatology. 45 938 947 17393520 10.1002/hep.21622 1:CAS:528: DC%2BD2sXltlWitrw%3D
30. M Chuma M Sakamoto K Yamazaki T Ohta M Ohki M Asaka, et al. 2003 Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma Hepatology. 37 198 207 12500205 10.1053/jhep.2003.50022 1:CAS:528:DC%2BD3sXovVWhuw%3D%3D
31. CC Huang TJ Lee PH Chang YS Lee CC Chuang YJ Jhang, et al. 2010 Expression of cathepsin S and its inhibitor stefin A in sinonasal inverted papilloma Rhinology. 48 352 357 21038029
32. J Quackenbush 2001 Computational analysis of microarray data Nat Rev Genet. 2 418 427 11389458 10.1038/35076576 1:CAS:528:DC%2BD3MXktlKqtbg%3D
33. Raychaudhuri S, Stuart JM, Altman RB. Principal components analysis to summarize microarray experiments: application to sporulation time series. Pac Symp Biocomput. 2000:455-66.
34. MW Smith ZN Yue GK Geiss NY Sadovnikova VS Carter L Boix, et al. 2003 Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma Cancer Res. 63 859 864 12591738 1:CAS:528: DC%2BD3sXht1GqsLs%3D
35. H Ishii J Yamamoto T Ikari 2008 Adjuvant treatments for resectable hepatocellular carcinoma J Hepatobiliary Pancreat Surg. 15 459 462 18836796 10.1007/s00534-008-1359-1
36. AL Cheng YK Kang Z Chen CJ Tsao S Qin JS Kim, et al. 2009 Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol. 10 25 34 19095497 10.1016/S1470-2045(08) 70285-7 1:CAS:528:DC%2BD1cXhsFChtbnM
37. HK Seitz F Stickel 2007 Molecular mechanisms of alcohol-mediated carcinogenesis Nat Rev Cancer. 7 599 612 17646865 10.1038/nrc2191 1:CAS:528:DC%2BD2sXotVKqsr0%3D
38. SP Liu YS Li CM Lee CH Yen YJ Liao SF Huang, et al. 2011 Higher susceptibility to aflatoxin B(1)-related hepatocellular carcinoma in glycine N-methyltransferase knockout mice Int J Cancer. 128 511 523 20473876 10.1002/ijc.25386 1:CAS:528:DC%2BC3cXhsVOktL7F
39. JC Ho ST Cheung KL Leung IO Ng ST Fan 2004 Decreased expression of cytochrome P450 2E1 is associated with poor prognosis of hepatocellular carcinoma Int J Cancer. 111 494 500 15239125 10.1002/ijc.20282 1:CAS:528:DC%2BD2cXmsFeqtb8%3D
40. T Nakatsura Y Yoshitake S Senju M Monji H Komori Y Motomura, et al. 2003 Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker Biochem Biophys Res Commun. 306 16 25 12788060 10.1016/S0006-291X(03)00908-2 1:CAS:528:DC%2BD3sXkt1GhsL0%3D
41. M Sakamoto 2009 Early HCC: diagnosis and molecular markers J Gastroenterol. 44 108 111 19148803 10.1007/s00535-008-2245-y 1:CAS:528:DC%2BD1MXosVKjsA%3D%3D
42. H Liu P Li Y Zhai CF Qu LJ Zhang YF Tan, et al. 2010 Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma World J Gastroenterol. 16 4410 4415 20845507 10.3748/wjg.v16.i35.4410 1:CAS:528:DC%2BC3cXhtF2rsLvK
43. GH Yang J Fan Y Xu SJ Qiu XR Yang, et al. 2008 Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection Oncologist. 13 1155 1165 18997126 10.1634/theoncologist.2008-0081 1:CAS:528:DC%2BD1MXmtVGjtA%3D%3D
44. PV Korita T Wakai Y Shirai Y Matsuda J Sakata X Cui, et al. 2008 Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma Hum Pathol. 39 1777 1783 18701136 10.1016/j.humpath.2008.05.006 1:CAS:528:DC%2BD1cXhtlyltb%2FF
45. RX Chen YH Xia JF Cui TC Xue SL Ye 2010 Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection J Gastroenterol Hepatol. 25 1435 1442 20659235 10.1111/j.1440-1746.2010.06277.x 1:CAS:528:DC%2BC3cXhtFahsLnL
46. V Takafuji M Forgues E Unsworth P Goldsmith XW Wang 2007 An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma Oncogene. 26 6361 6371 17452979 10.1038/sj.onc.1210463 1:CAS:528: DC%2BD2sXhtV2is73K
47. T Ue H Yokozaki Y Kitadai S Yamamoto W Yasui T Ishikawa, et al. 1998 Co-expression of osteopontin and CD44v9 in gastric cancer Int J Cancer. 79 127 132 9583725 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V 1:CAS:528:DyaK1MXksl2kurw%3D
48. SH Kim YH Chung SH Yang JA Kim MK Jang SE Kim, et al. 2009 Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization Korean J Hepatol. 15 320 330 19783881 10.3350/kjhep.2009.15.3.320 1:CAS:528:DC%2BD1MXksVOjt7o%3D